Abstract
Cardiovascular disease is the leading cause of mortality and morbidity in patients with different stages of chronic kidney disease (CKD). The phenotypic picture of cardiovascular disease differs between those on dialysis and patients with early stages of chronic kidney disease. Whilst atherosclerotic coronary artery disease is common in the early stages of CKD, arrhythmias, congestive cardiac failure and sudden cardiac death (SCD) prevail in ESRD patients on dialysis, thus confounding interventions. Lipids profile also differs between both stages with high cholesterol levels being common at early CKD stages with relatively well-nourished patients compared to normal or low cholesterol levels in ESRD patients treated by dialysis who are usually under- or malnourished; reverse epidemiology. Lipid profiles also differ between haemodialysis and peritoneal dialysis patients; due to the high caloric content of peritoneal dialysis fluids, patient treated by this modality have higher triglycerides levels.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Moorhead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet. 1982;2(8311):1309–11.
Expert Panel on Detection Evaluation, Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486–97.
National Kidney Foundation. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis. 2003;41:S1–92.
KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney Int. 2013;suppl 3(3):259–305.
Jaber BL, Madias NE. Atorvastatin in patients with type 2 diabetes mellitus undergoing dialysis. N Engl J Med. 2005;353(17):1858–60.
Montori VM, Permanyer-Miralda G, Ferreira-González I, Busse JW, Pacheco-Huergo V, Bryant D, Alonso J, Akl EA, Domingo-Salvany A, Mills E, Wu P, Schünemann HJ, Jaeschke R, Guyatt GH. Validity of composite end points in clinical trials. BMJ. 2005;330(7491):594–6.
Shurraw S, Tonelli M. AURORA: is there a role for statin therapy in dialysis patients? Am J Kidney Dis. 2010;55(2):237–40.
Holdaas H, Holme I, Schmieder RE, Jardine AG, Zannad F, Norby GE, Fellström BC, AURORA Study Group. Rosuvastatin in diabetic hemodialysis patients. J Am Soc Nephrol. 2011;22(7):1335–41.
Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E, German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. NEJM. 2005;353(3):238–48.
Upadhyay A, Weiner DE. Lipid lowering therapy in individuals with CKD: lessons learned from SHARP. Am J Kidney Dis. 2012;59(2):170–3.
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet. 2005;366(9493):1267–78.
Kasiske BL, K/DOQI Dyslipidemia Work Group. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients. Am J Transplant. 2005;5(6):1576.
Fellström B, Holdaas H, Jardine AG, Holme I, Nyberg G, Fauchald P, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambühl P, Olsson AG, Hartmann A, Logan JO, Pedersen TR, Assessment of Lescol in Renal Transplantation Study Investigators. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney Int. 2004;66(4):1549–55.
Abedini S, Holme I, März W, Weihrauch G, Fellström B, Jardine A, Cole E, Maes B, Neumayer HH, Grønhagen-Riska C, Ambühl P, Holdaas H, ALERT Study Group. Inflammation in renal transplantation. Clin J Am Soc Nephrol. 2009;4(7):1246–54.
Palmer SC, Navaneethan SD, Craig JC, Perkovic V, Johnson DW, Nigwekar SU, Hegbrant J, Strippoli GF. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst Rev. 2014;28:1.
Vashistha T, Mehrotra R, Park J, Streja E, Dukkipati R, Nissenson AR, Ma JZ, Kovesdy CP, Kalantar-Zadeh K. Effect of age and dialysis vintage on obesity paradox in long-term hemodialysis patients. Am J Kidney Dis. 2014;63(4):612–22.
Drechsler C, Grootendorst DC, Pilz S, Tomaschitz A, Krane V, Dekker F, März W, Ritz E, Wanner C. Wasting and sudden cardiac death in hemodialysis patients: a post hoc analysis of 4D (Die Deutsche Diabetes Dialyse Studie). Am J Kidney Dis. 2011;58(4):599–607.
Wanner C, Tonelli M, Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85(6):1303–9.
Ritz E, Wanner C. Lipid abnormalities and cardiovascular risk in renal disease. J Am Soc Nephrol. 2008;19(6):1065–70.
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
El Kossi, M. (2015). Lipids and Chronic Kidney Disease Clinical Trials: A Critical Appraisal. In: El Kossi, M., Khwaja, A., El Nahas, M. (eds) Informing Clinical Practice in Nephrology. Springer, Cham. https://doi.org/10.1007/978-3-319-10292-4_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-10292-4_7
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-10291-7
Online ISBN: 978-3-319-10292-4
eBook Packages: MedicineMedicine (R0)